Meta-analysis of 7 RCTs (1300 patients) in ovarian cancer: adding HIPEC to interval cytoreductive surgery in newly diagnosed disease improved PFS (HR 0.65) and OS (HR 0.68), with no significant benefit in recurrent disease. Grade ≥3 AEs 45.7% vs 36.4% (NS).
Meta-analysisn = 1,300
Altayf et al. The role of hyperthermic intraperitoneal chemotherapy in newly diagnosed and recurrent ovarian cancer: A time-to-event meta-analysis of randomized trials